New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
08:49 EDTABMDAbiomed shares overvalued, says Northland Securities
Northland believes Abiomed utilization rates for Impella are going down on both the ImpellaCP and Impella 2.5. The firm said Abiomed's story is now dependent on new site add-ons where utilization rates haven moved and sees risk to shares. The firm rates Abiomed an Underperform with a $14 price target.
News For ABMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 17, 2015
08:00 EDTABMDAbiomed price target raised to $72 from $60 at Leerink
Subscribe for More Information
08:00 EDTABMDAbiomed price target raised to $72 from $60 at Leerink
Leerink raised its price target for Abiomed shares to $72 saying it believes recent adoption momentum is sustainable as the company continues to penetrate the emergent and high risk percutaneous coronary intervention patient population. It reiterates an Outperform rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use